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Abstract
Background: Reports of acquired immunodeficiency due to autoantibodies against interferon gamma in the adult
population are increasing. The interleukin-12-dependent interferon-gamma axis is a major regulatory pathway of
cell-mediated immunity and is critical for protection against a few intracellular organisms, including
non-tuberculous mycobacteria and Salmonella spp. We report the first case of a fatal disseminated Mycobacterium
colombiense/cytomegalovirus coinfection in an adult woman associated with the acquisition of autoantibodies
against interferon-gamma.
Case presentation: A 49-year-old woman, born to nonconsanguineous parents in Laos, but who had lived in
Canada for the past 30 years, presented with a 1-month history of weight loss, fatigue, cough, and intermittent
low-grade fever. A thoracic computed tomography scan revealed an 8 × 7 cm irregular mass impacting the right
superior lobar bronchus along with multiple mediastinal and hilar adenopathies. On the fourth day of admission,
the patient developed fever with purulent expectorations. Treatment for a post-obstructive bacterial pneumonia
was initiated while other investigations were being pursued. Almost every culture performed during the patient’s
hospitalization was positive for M. colombiense. Given the late presentation of symptoms - at the age of 49 years
- and the absence of significant family or personal medical history, we suspected an acquired immunodeficiency
due to the presence of anti-interferon-gamma autoantibodies. This was confirmed by their detection at high levels
in the plasma and a STAT1 phosphorylation assay on human monocytes. The final diagnosis was immunodeficiency
secondary to the production of autoantibodies against interferon-gamma, which resulted in a post-obstructive
pneumonia and disseminated infection of M. colombiense. The clinical course was complicated by the presence of a
multiresistant Pseudomonas aeruginosa post-endobronchial ultrasound mediastinitis, cytomegalovirus pneumonitis
with dissemination, and finally, susceptible P. aeruginosa ventilator-associated pneumonia with septic shock and
multiple organ failure, leading to death despite appropriate antibacterial and anti-mycobacterial treatment.
Conclusions: Although rare, acquired immunodeficiency syndromes should be considered in the differential
diagnosis of patients with severe, persistent, or recurrent infections. Specifically, severe non-tuberculous
mycobacteria or Salmonella infections in adults without any other known risk factors may warrant examination of
autoantibodies against interferon-gamma because of their increasing recognition in the literature.
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Background
Disseminated non-tuberculous mycobacteria (NTM)
infections mainly occur in individuals with impaired
cell-mediated immunity, which may result from human
immunodeficiency virus (HIV) infection, malignancy
(especially hematologic cancers), the use of immuno-
suppressive drugs, and, more rarely, primary T-cell
deficiencies [1]. The interleukin-12 (IL-12)-dependent
interferon-gamma (IFN-γ) axis is a major regulatory
pathway of cell-mediated immunity and is critical for
protection against some intracellular organisms, includ-
ing NTM and Salmonella spp. [2]. Genetic defects in this
axis among the pediatric population, producing Mende-
lian susceptibility to mycobacterial diseases (MSMD), are
well recognized [2,3]. However, since 2004, reports of
severe, persistent, or recurrent infections with NTM
secondary to acquired autoantibodies to IFN-γ have been
increasingly encountered among the adult population [4].
In this study, we report the first case of a fatal dissemi-
nated Mycobacterium colombiense/cytomegalovirus coin-
fection in an adult woman associated with the acquisition
of autoantibodies against IFN-γ.
Case presentation
A 49-year-old woman, born to nonconsanguineous par-
ents in Laos, but who had lived in Canada for the past
30 years, presented in May 2010 with a 1-month history
of weight loss, fatigue, cough, and intermittent low-
grade fever. Her previous family and personal medical
history were unremarkable. She could not recall being in
contact with tuberculosis. Given that a 7-day course of
levofloxacin treatment for presumed right lung pneumo-
nia did not improve her symptoms, she was subjected to
further examinations. An initial bronchoscopy showed
friable, bleeding, and irregular mucosa of the right upper
lobe entry. Biopsies were not feasible, but Ziehl-Neelsen
and auramine stains of the bronchoalveolar lavage (BAL)
were negative and cytology was normal. A thoracic com-
puted tomography (CT) scan revealed atelectasis caused
by an 8 × 7 cm irregular mass impacting the right
superior lobar bronchus along with multiple mediastinal
and hilar adenopathies (Figure 1a).
Since the most probable diagnosis was a neoplastic
process, the patient was discharged home to await a
scheduled transthoracic biopsy (TTB). However, when a
previous BAL culture was found to be positive for acid-
fast bacilli (AFB), she was readmitted to rule out active
tuberculosis. Upon presentation, she was afebrile and
her vital signs were normal. There was no regional
adenopathy, and the physical examination was normal
except for reduced vesicular murmur sounds on auscul-
tation over the right lung. The peripheral white blood
cell count was 26 × 109/L, with 21 × 109/L neutrophils
and 3 × 109/L lymphocytes. The inflammatory syndrome
was considered important due to a serum C-reactive
protein concentration of 111 mg/L and erythrocyte sedi-
mentation rate of 25 mm/h. The procalcitonin concen-
tration was 19 μg/L. The hemoglobin level was 71 g/L
with a mean corpuscular volume of 73 fL, and the plate-
let count was at 766 × 109/L. Other routine biochemical
tests were normal. Polymerase chain reaction (PCR) per-
formed 3 days after admission, using morning sputum,
was negative for Mycobacterium tuberculosis complex.
On the fourth day, the patient developed fever with
purulent expectorations. While other investigations were
being pursued, treatment for post-obstructive pneumo-
nia was initiated with piperacillin-tazobactam.
An endobronchial ultrasound (EBUS) revealed puru-
lent secretions and a diminished right superior lobar
bronchus caliber. Multiple transbronchial needle aspira-
tions of adenopathies were also performed. Two days
later, the patient’s condition necessitated her transfer to
the intensive care unit (ICU), and vancomycin was
added. The peripheral white blood cell count was 47 ×
109/L and a chest X-ray film showed a new infiltration
process affecting the right lower lobe and median lobe
with an important pleural effusion. Analysis of the
pleural fluid showed an uncomplicated exudative effu-
sion (pH >7.2) with a predominance of lymphocytes. On
the fourth day in the ICU, endotracheal intubation and
Figure 1 a Thoracic CT scan at presentation. Irregular mass impacting the right superior lobar bronchus. b Thoracic CT scan on the eighth day
in the ICU. Extensive right pulmonary consolidation.
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support with amines were required for septic shock. The
results of mediastinoscopy biopsies followed by a TTB of
the mass lesion were non-diagnostic, showing only ex-
tensive fibrosis and unspecific acute and chronic reactive
lymphoid infiltrates. Granuloma formation was not
observed.
On the eight day in the ICU, the first preliminary
report of the initial BAL sample revealed that it was
positive for M. colombiense, as shown by analyzing ge-
nomic deletions and rRNA 16S gene sequencing (Quebec
Public Health Laboratory). As radiologic control had also
deteriorated (Figure 1b), the decision to commence treat-
ment on the same day with rifampicin, clarithromycin,
and ethambutol was taken. Later sensitivity analysis by
broth microdilution revealed that M.colombiense was sus-
ceptible to clarithromycin with a minimum inhibitory
concentration (MIC) of 0.25 mg/L. Rifampin's MIC was
4 mg/L and ethambutol's MIC was >16 mg/L. Although
ethambutol and rifampin are useful clinically in cases of
Mycobacterium avium complex infections [5], breakpoints
for determining susceptibility and resistance have not
been established by the Clinical and laboratory standards
institute M24-A2 (CLSI M24-A2) [6]. HIV tests were re-
peatedly negative. Two days later, multiple organ failure
(MOF) developed. Since the previous mediastinoscopy
culture was positive for a multiresistant Pseudomonas
aeruginosa strain (Table 1), vancomycin was stopped and
piperacillin-tazobactam was changed to doripenem and
tobramycin. On the patient’s 27th day in the ICU, admin-
istration of anti-Pseudomonas antibiotics was terminated
because her clinical condition was stable. However, when
2 tracheal aspirates were found to be positive for suscep-
tible P. aeruginosa (Table 1) and clinical deterioration was
again noted, treatment with piperacillin-tazobactam and
ciprofloxacin was started. Unfortunately, the patient died
from septic shock with MOF on the 34th day in the ICU.
Interestingly, almost every culture performed during the
patient’s hospitalization was positive for M. colombiense
(Table 1). Although cytomegalovirus (CMV) serology was
not performed for this patient before her death, samples
from the final bronchoscopy grew CMV in fibroblast cell
culture many days later (Table 1). The pathologist also
identified CMV inclusions in the lungs, mediastinal ade-
nopathies, thyroid gland, pancreas, and adrenal glands
(Figure 2a). This observation was also confirmed by
immunohistochemistry (Figure 2b).
Post-mortem examination of the right lung revealed
an organizing pneumonia, and the mediastinum con-
tained a lot of adherence, fibrosis, and adenopathies with
lymphoid hyperplasia. No granuloma formation was
detected in the lungs or in any of the other organs
examined. An immunologic investigation performed be-
fore the death of our patient revealed normal counts of
lymphocyte populations (CD4+, CD8+, CD19+, CD56+)
and normal levels of immunoglobulins. We concluded
that a genetic immunological deficit was very unlikely
because of the late presentation of symptoms—at the
age of 49 years—and the absence of significant family or
personal medical history. Instead, we suspected an
acquired deficit; thus, we tested for the presence of anti-
IFN-γ autoantibodies in the patient’s plasma. The IFN-γ
titer—defined as the dilution of a patient’s plasma that
inhibits 50% fixation of 125 pg/mL IFN-γ in a standard
IFN-γ ELISA assay (eBioscience ELISA kit)—was positive
at 1:53725. Therefore, the final diagnosis was immunodefi-
ciency secondary to the production of autoantibodies
against IFN-γ, which resulted in post-obstructive pneumo-
nia caused by lymphadenitis and disseminated infection of
Table 1 Culture specimens during the patient’s hospitalization
Specimen Date Auramine NTM Other
BAL 7/6/10 - M. colombiense -
Sputum 27/6/10 - M. colombiense -
Sputum 28/6/10 1–9/100 M. colombiense -
EBUS 30/6/10 - M. colombiense -
Sputum 2/7/10 - - C. albicans
Mediastinoscopy 6/7/10 - M. colombiense P. aeruginosa
Tracheal aspirate 8/7/10 1–9/100 M. colombiense -
Tracheal aspirate 9/7/10 1–9/100 M. colombiense -
Tracheal aspirate 10/7/10 1–9/100 M. colombiense -
Right pleural effusion 11/7/10 - M. colombiense -
Bronchial lavage 18/7/10 1–2/100 M. colombiense -
Bronchial lavage 26/7/10 - M. colombiense -
Bronchial lavage 29/7/10 - - CMV
Tracheal aspirate 31/7/10 - - P. aeruginosa
Tracheal aspirate 2/8/10 - M. colombiense P. aeruginosa
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M. colombiense. The clinical course was complicated by
the presence of multiresistant P. aeruginosa infection
post-EBUS mediastinitis, CMV pneumonitis with dissem-
ination, and finally, susceptible P. aeruginosa ventilator-
associated pneumonia with septic shock and MOF leading
to death.
Discussion
A total of 29 cases of disseminated NTM infections
secondary to the production of autoantibodies against
IFN-γ had been reported [1,2,7,8] before the recent large
prospective study by Browne et al. [9]. Compared to
control groups, neutralizing anti-IFN-γ autoantibodies
was associated with disseminated NTM or other differ-
ent opportunistic infections among more than 80
patients from Thailand or Taiwan. In these studies, the
organs involved included the lymph nodes, bone mar-
row, bones, lungs, skin, and soft tissues. In contrast to
the case reported here, most of them described the for-
mation of complete or poorly formed granulomas. How-
ever, several different forms of MSMD are associated
with the absence of granuloma formation [10,11], sug-
gesting that our observations may be plausible. Positive
blood cultures were infrequently noted [1]. The presence
of both rapidly growing NTMs (e.g., M. chelonae, M. for-
tuitum, and M. abscessus) and slowly growing NTMs
(e.g., M. avium complex (MAC), M. szulgai, M. kansasii,
M. scrofulaceum, andM. intermedium) has been described,
and the most frequently detected are MAC and M. chelo-
nae. Notably, to our knowledge, our case is the first to
specifically identify M. colombiense. In fact, M. colom-
biense is a novel member of the Mycobacterium avium
complex (MAC) that was first isolated in 2006 from blood
specimens of four HIV-positive patients in Colombia,
South America [12]. Interestingly, only 3 reports have
shown its capability of causing lymphadenitis, and they
were from cervical [13,14] or subclavicular lymph nodes
[15]. It was also isolated only twice from respiratory
specimen [14]. Previous identifications of MAC organisms
often relied on hybridization techniques, which hampered
distinguishing between the various MAC species com-
pared to current sequence-based identifications and geno-
typing [14]. Because no consensus about the preferred
anti-mycobacterial regimen exists yet for M. colombiense,
we followed current disseminated Mycobacterium avium
complex infections guidelines using clarithromycin with ri-
fampin and ethambutol [5].
Pathogens other than NTM or Salmonella spp. have
been reported as coinfecting organisms in patients with
acquired autoantibodies against IFN-γ. Namely, these in-
clude M. tuberculosis, varicella-zoster virus, Burkholderia
cocovenenans, Candida, Aspergillus, Achromobacter spp.,
Enterococcus spp., Streptococcus pyogenes, Penicillium
marneffei, Strongyloides stercoralis, Cryptococcus neoformans
and Histoplasma capsulatum [1,2,8,9]. However, the dir-
ect involvement of these coinfecting organisms in the
defect in the IL-12―dependent IFN-γ axis is not entirely
clear. Moreover, Pseudomonas spp. have only been
described once in coinfection [16]. Since our patient had
several other risk factors for P. aeruginosa infection (e.g.,
ICU, endotracheal intubation, and antibiotics) and be-
cause Pseudomonas is not an intracellular pathogen, it
seems unlikely to be a direct consequence of a defect in
the IL-12―dependent IFN-γ axis. Post-mortem serum
sample was collected to measure CMV-specific immuno-
globulin G (CMV-IgG) and CMV-specific immunoglobu-
lin M (CMV-IgM) markers. As our patient was IgM
negative, and IgG positive, we assumed that the CMV
infection was most likely a reactivation process. Prior to
our report, CMV coinfection had only been described in
1 case [4] of acquired autoantibodies against IFN-γ.
However, cases of CMV infection have been described
in MSMD [3,17]. Therefore, it is possible that the IL-
12―dependent IFN-γ axis, strongly diminished by
autoantibodies in our patient, played a significant role
in her disseminated CMV infection.
Figure 2 a CMV inclusion. Histological analysis of the lung reveals a very large cell that displays a large violet intranuclear inclusion with a small
clear halo (typical owl-eye inclusion; arrow). b CMV immunohistochemistry. Immunohistochemical analysis of the lung reveals anti-CMV positive
cells (arrows).
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Similar to the patient described in the present study,
cases of acquired autoantibodies against IFN-γ have
mainly been reported in Asian female patients [1].
Nonetheless, this is the first reported case from Laos.
The high incidence rate in Asian populations may be
associated with an unknown HLA allele variant [2]. In
contrast to what is sometimes observed, our patient did
not present any known autoimmune endocrinopathy or
reactive skin diseases such as Sweet’s syndrome or pus-
tular psoriasis [1,2]. Given the severe presentation of our
case and the high titer of autoantibodies detected, we
hypothesize that such autoantibodies would produce a
strong inhibitory effect against IFN-γ signal transduction
and IFN-γ―dependent upregulation of TNF-α and IL-12,
as was previously shown by Patel et al. [16]. Naturally oc-
curring anti-IFN-γ autoantibodies have been previously
described in cases of viruses and mycobacteria infections.
However, they usually occurred at low titers and were bio-
logically inactive [16,18]. To confirm our hypothesis, we
performed a STAT1 (implicated in the IFN-γ―dependent
upregulation of TNF-α and IL-12 [19]) phosphorylation
assay using FACSCanto flow cytometry (BD Biosciences)
on preserved plasma sample (Figure 3). As expected,
phosphorylation of STAT1 in human monocytes after
stimulation with INF-γ was inhibited by the patient's
plasma, but not when the monocytes were stimulated with
IFN-α. We also tested HIV serology twice, and found the
immunologic screening to be normal. Since the patient
was not known to have any other risk factor for depressed
cell-mediated immunity, it is likely that our diagnosis is
accurate.
Outcomes in cases of acquired autoantibodies to IFN-
γ with NTM infections in the adult population range
from fatal infection to complete recovery. These cases
frequently result in refractory infection with recurrent or
relapsing episodes, despite aggressive and prolonged
treatment with 3 or more anti-mycobacterial agents.
Additional adjunctive therapies—such as plasmapheresis,
intravenous immunoglobulins, exogenous IFN-γ, and
cyclophosphamide followed by corticotherapy—have been
reported with varying rates of success. In a recent study
by Browne et al. [7], 4 cases of refractory disease treated
with rituximab showed clinical, radiological, and labora-
tory evidence of therapeutic improvement, including
improved IFN-γ signaling and reduction in anti-IFN-γ
autoantibody levels. The rare fatal cases [4,8,20] described
by Browne and colleagues were infections that did not
respond to months of anti-mycobacterial therapy. There-
fore, we believe that our patient is the first to present a
fulminant evolution, which led to death in her first
hospitalization. This may be explained by the stepwise
addition of severe Pseudomonas and disseminated CMV
coinfections in a patient already weakened by NTM infec-
tion. Despite early initiation (on the same day as the
preliminary mycobacterial culture result was known) of
anti-mycobacterial treatment based on current recom-
mendations for Mycobacterium avium complex dissemi-
nated infections, it is likely that the other coinfections had
progressed significantly enough to cause mortality.
Staining of blood samples for STAT1 phosphorylation
One hundred microliter (μl) of normal heparinized
whole blood were incubated or not either with 20μl of
IFN-γ (10000 IU/ml) or IFN-α (10000 IU/ml) premixed
with patient plasma or control plasma (V/V:1/1) for 15
minutes at 37°C. Erythrocytes were lysed with BD
phosflow™ Lyse/Fix Buffer (1X) for 10 minutes at 37°C.,
After surface staining with FITC-conjugated anti-CD14
antibody, cells were permeabilized with BD phosflow™
Perm Buffer III, followed by intracellular staining with
Alexa 647-conjugated antibody recognizing pSTAT1
(Y701). Data acquisition was performed by FACSCanto
flow cytometry (BD Biosciences) and analysed with FCS
Express 4 Flow Research Edition. Fluorescence histogram
displays STAT1 phosphorylation gated on CD14+ popula-
tion (Figure 3).
Conclusions
This case demonstrates that, although rare, primary or
acquired immunodeficiency syndromes should be consid-
ered in the differential diagnosis of patients with severe,
persistent, or recurrent infections. Specifically, severe
NTM or Salmonella infections in adults without any other
known risk factors may warrant examination of autoanti-
bodies against IFN-γ. Early recognition is vital in such
cases in order to consider suitable treatment options, in-
cluding, for example, the use of rituximab [7,19].
Consent
Written informed consent was obtained from the next
of kin of the patient for publication of this case report
and any accompanying images. A copy of the written
Figure 3 Inhibition of INF-γ-induced STAT1 phosphorylation in
control monocytes by patient’s plasma. Fluorescence histogram
displays STAT1 phosphorylation gated on CD14+ (monocytes)
population. Whole blood samples were incubated without (−−–) or
with INF-γ (1000 IU/ml)(left panel), or with INF-α (1000 IU/ml) (Right
panel) pre-mixed with patient plasma (—) or control plasma (—).
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